Published by Frank Prenesti on 6th June 2022
(Sharecast News) - A treatment for breast cancer developed by AstraZeneca and Daiichi Sankyo has been shown to double the progression-free survival rates of patients compared with chemotherapy, according to trial data released on the weekend at a conference.
URL: http://www.digitallook.com/dl/news/story/32726610/...